Counterproductive Work Behaviours (CWB) refer to negative behaviours in the workplace that hinder organizational effectiveness. CWB ranges from violence and harassment to stealing and drug consumption on the job. Despite its importance and prevalence, little attention has been paid to leader CWB, as the focus has been mainly on employee CWB. Leader CWB, could be largely attributed to negative aspects of individuals’ personality. Therefore, the first objective is to discover what types of personality based CWB are more prevalent in leaders.
Competency-based management (CBM) is an approach to human resource management (HRM) that has grown in popularity over the years. CBM involves objectively defining the necessary competencies (defined as job-related knowledge, skills, abilities, and other attributes) to effectively perform a job, then integrating this framework into the organizations HRM processes. While this approach makes sense in theory, there is little hard evidence available about its effectiveness for organizations.
Wearable devices such as smart watches are increasingly being used for clinical applications. The Octopus Watch, developed by Joy, helps children structure their days by giving reminders about upcoming events. Our pilot studies have shown that the watch may also be used in suggestion-based healing paradigms to improve self-regulation, focus, and relaxation in children with behavioural disorders.
G protein coupled receptors (GCPRs) are proteins found at the surface of cells are responsible for activating numerous intracellular signaling pathways and thus are involved in regulating about every physiological response. Activation of GPCRs occurs by compounds as varied as photons, lipids, ions, small hormonal or neurotransmitter compounds or larger peptidic and protein molecules. As such, GPCRs are currently the target of up to 34% of marketed drugs.
Pharmacotherapy is one of the primary treatments for psychiatric disorders. Given the variation in individual response, and the current trial-and-error treatment, a more personalized approach is needed. The Mitacs Elevate postdoctoral fellow project involves the use of pharmacogenetic testing to personalize medication prescriptions for patients, and the commercialization of pharmacogenetic testing.
Mild Traumatic Brain Injury (mTBI) is a common and devastating condition that severely affects millions of people around the world. Following an mTBI, also known as concussion, a medical professional performs standard neurological tests, however, these tests are very subjective, based on patient-reporting, and provide little to no insight on the severity of an mTBI. The company TBIFinder therefore revolutionizes brain injury treatment by providing a fully objective service that uses a Magnetic Resonance Imaging (MRI) machine to assess mTBIs.
Understanding the factors that influence the financial decisions that individuals make is particularly important in difficult economic times. The proposed research seeks to understand the factors that influence financial decision-making under economic stress, with a particular interest in the efficacy of interventions to influence decision-making and the role of financial literacy and related constructs.
Alzheimers disease (AD) is the most common neurodegenerative disorder. SignalChem LifeSciences Corp. recently developed a potent small molecule inhibitor (SLC-0149) for targeting CAIX, a hypoxia inducible gene, in the application of treating cancers. Since hypoxia has been implicated as a factor to facilitate AD development, this study aims to explore the potentiality of applying SLC-0149 to treat AD model mice. More specifically, we will focus on the effects of SLC-0149 on two neuropathological features in AD, including A? deposition and Tau phosphorylation.
The world is aging rapidly and healthy cognitive aging a major healthcare priority. Thus, a better understanding of how the brain changes with normal aging versus pathology is required. Advancements in wearable technologies may allow the assessment of brain function with greater ease, accessibility, and at a lower cost, as compared with traditional neuroimaging techniques. Currently, commercially available portable electroencephalogram (EEG) device offers the potential to evaluate brain function. However, this needs to be tested and validated.
Alzheimers disease is the most common neurodegenerative disorder. The recent immunotherapy brings the hope of treating AD as suggested by several preclinical studies. This project first aims to develop a humanized monoclonal antibody to target the molecules involved in generating a toxic protein of AD, named amyloid ?, and test the application of this antibody in treating AD model mice. In addition, early diagnosis of AD is of great need to achieve the maximal effectiveness of beneficial treatments.